How to Read TB-500 COA — What Purity Means | Real Peptides

A peptide supplier hands you a Certificate of Analysis claiming 98.7% purity for TB-500 (Thymosin Beta-4). The number looks reassuring. But a COA from a contract lab in Eastern Europe once showed identical purity claims for three structurally different peptides—identical down to the second decimal. The HPLC chromatogram patterns were impossible given the molecular weight differences, yet the supplier distributed them as legitimate verification documents. The problem wasn't forgery—it was that nobody reading those COAs understood what the data was supposed to look like when genuine.

Our team has evaluated hundreds of peptide COAs across suppliers for research procurement. The gap between a document that looks official and one that actually verifies purity comes down to knowing which data points cannot be fabricated without specialized equipment—and which can be typed into any PDF template.

How do you accurately read a TB-500 Certificate of Analysis for research verification?

To read a TB-500 COA correctly, verify the analytical method lists HPLC or LC-MS (not gravimetric or visual), confirm the purity percentage matches the area-under-curve integration from the chromatogram, cross-check that reported impurities sum with the purity claim to approximately 100%, and ensure the batch number on the COA matches the vial label exactly. A legitimate COA includes chromatogram traces, not just summary statistics—those traces contain peak patterns unique to TB-500's 43-amino-acid sequence that cannot be replicated for a different compound.

Most researchers assume the percentage is the entire story. It's not. A COA is three documents compressed into one: a purity assertion, a methodology disclosure, and an impurity fingerprint. Missing any layer means you're trusting a number without understanding what it quantifies. This article covers how to interpret HPLC chromatograms for TB-500 specifically, what the impurity breakdown should show for a synthetic peptide, how batch traceability prevents substitution, and which COA red flags indicate the document wasn't generated from actual testing.

Step 1: Verify the Analytical Method Used to Determine Purity

The methodology section determines whether the purity claim is verifiable or arbitrary. HPLC (High-Performance Liquid Chromatography) separates TB-500 from impurities based on molecular interaction with a stationary phase—producing a chromatogram where each peak represents a distinct molecular species. The area under TB-500's retention peak, divided by total peak area, yields the purity percentage. LC-MS (Liquid Chromatography-Mass Spectrometry) adds mass verification, confirming the peak corresponds to TB-500's exact molecular weight of 4963.4 Da.

Gravimetric methods—listing purity as a weight percentage—cannot distinguish TB-500 from structurally similar impurities or even from lyophilization salts like mannitol. A gravimetric purity claim of 98% could mean 98% peptide content or 98% total solid material including excipients. Visual inspection methods are meaningless for molecular verification. If the COA lists 'appearance: white powder' as the primary quality metric without HPLC data, the purity claim is unsupported.

Our team has found that legitimate research-grade suppliers default to HPLC because it's the FDA-recognized standard for peptide identity verification under 21 CFR 211.165(e). The chromatogram itself—not the summary statistic—is the proof. Request the raw chromatogram file if only a purity percentage appears on the COA. Suppliers using actual third-party labs will provide it. Suppliers generating COAs internally without testing cannot.

The method detection limit matters for trace impurities. HPLC at 220nm wavelength detects peptide bonds down to 0.1–0.5% concentration. If the COA claims 'no detectable impurities' without listing a detection threshold, the method sensitivity is unknown—meaning low-level contaminants could be present but unquantified. For TB-500 research applications involving cell culture or animal models, impurity thresholds below 2% total are standard.

Step 2: Cross-Reference the Purity Percentage Against the Chromatogram Data

The chromatogram shows time on the x-axis and detector response on the y-axis. TB-500 elutes at a specific retention time based on the column type and mobile phase—typically 8–12 minutes on a C18 reverse-phase column with acetonitrile gradient elution. The dominant peak should appear at this retention time with minimal baseline noise before or after. Integration software calculates the area under this peak and divides it by total detected area to produce the purity percentage.

A legitimate COA includes the chromatogram with integration markers visible. The start and end points of each peak should be clearly defined—not manually adjusted to exclude shoulder peaks or baseline drift. If the TB-500 peak shows a purity of 98.3% but a smaller adjacent peak at 7.8 minutes is unlabeled, that secondary peak represents an impurity (likely a deletion sequence or oxidized variant) that should reduce the reported purity. Excluding it from integration inflates the number artificially.

Peak symmetry indicates synthesis quality. TB-500 synthesized via solid-phase peptide synthesis (SPPS) should produce a sharp, symmetric Gaussian peak. Tailing or fronting suggests incomplete purification or column degradation during analysis. A tailing factor above 1.5 (measured as the ratio of peak width at 5% height to twice the front half-width) often correlates with impurity co-elution—the purity claim may be accurate for the retention time window but miss impurities eluting in the tail.

The baseline between peaks should return to zero. If the baseline remains elevated between the TB-500 peak and adjacent peaks, unresolved impurities are present but not quantified. This is common in peptides shorter than 20 amino acids but unusual for TB-500's 43-residue sequence—its molecular weight and hydrophobicity create sufficient separation from truncation products under standard HPLC conditions. An elevated baseline suggests the gradient method wasn't optimized for this specific peptide.

Step 3: Interpret the Impurity Profile and Mass Spectrometry Confirmation

The impurity section lists what comprises the remaining percentage after the main purity claim. For TB-500 at 98% purity, the COA should account for the missing 2%—typically as deletion sequences (peptides missing one or more amino acids), insertion errors, or post-translational modifications like oxidation of methionine residues. If the impurity breakdown isn't listed, the 98% claim is incomplete.

Deletion sequences are the most common TB-500 impurities. SPPS coupling efficiency is 98–99% per amino acid addition, meaning a 43-residue peptide accumulates 0.5–2% deletion products even under optimal conditions. These appear as earlier eluting peaks on the chromatogram because shorter peptides are less hydrophobic. A COA showing one peak at 7.2 minutes (before the TB-500 peak at 10.1 minutes) labeled as 'deletion impurity: 1.3%' is consistent with SPPS synthesis. A COA showing no secondary peaks but claiming 98% purity is internally inconsistent.

Mass spectrometry confirms molecular weight. TB-500 (Thymosin Beta-4 fragment 1–43) has a monoisotopic mass of 4963.4 Da. LC-MS analysis should show a dominant ion at this mass within ±0.5 Da tolerance. If the COA lists HPLC purity but no MS confirmation, you're verifying retention time only—not molecular identity. Retention time can shift based on column age or mobile phase preparation, but molecular weight cannot. A peak eluting at the expected TB-500 retention time but showing mass 4947 Da indicates oxidation (loss of 16 Da from methionine or cysteine).

Trifluoroacetic acid (TFA) content should be quantified separately. TFA is used as an ion-pairing agent during HPLC purification and remains bound to the peptide after lyophilization. High TFA content (above 5% w/w) reduces effective peptide concentration and can interfere with cell-based assays. The COA should list TFA as a separate parameter measured by ion chromatography or 19F-NMR—not included in the peptide purity percentage. If TFA isn't mentioned, assume it's present but unquantified.

TB-500 COA: Component Comparison

Key Takeaways

• HPLC or LC-MS methodology is required to verify TB-500 purity—gravimetric or visual methods cannot distinguish the peptide from excipients or structural analogs.
• The chromatogram area-under-curve integration must match the stated purity percentage, and any secondary peaks should be labeled as quantified impurities.
• TB-500's molecular weight is 4963.4 Da—mass spectrometry confirmation is essential because retention time alone doesn't prove molecular identity.
• Deletion sequences from SPPS synthesis account for 0.5–2% of total impurities and should appear as earlier eluting peaks on the chromatogram.
• Batch number on the COA must match the vial label exactly—generic COAs issued for multiple batches indicate the document wasn't generated from that specific production run.
• TFA content above 5% w/w reduces effective peptide concentration and should be quantified separately, not included in the peptide purity percentage.

What If: TB-500 COA Scenarios

What If the COA Shows 98% Purity But No Chromatogram Is Included?

Request the raw HPLC chromatogram file from the supplier immediately. A purity percentage without supporting chromatogram data is unverifiable—the number could be accurate, estimated, or entirely fabricated. Legitimate third-party labs (like Colmaric Analyticals or Sigma-Aldrich Analytical Services) provide chromatograms as standard with every peptide COA because the integration calculation is visible in the trace itself. If the supplier cannot or will not provide the chromatogram, the COA wasn't generated from actual HPLC testing. Our team considers this a hard stop for procurement—no chromatogram means no verifiable purity claim regardless of what percentage appears on the document.

What If the Batch Number on the COA Doesn't Match the Vial Label?

Do not use that peptide for research until the discrepancy is resolved. Batch traceability exists to prevent suppliers from issuing one COA for multiple production runs or substituting a tested batch with an untested one. A mismatch indicates either administrative error (the wrong COA was attached to the shipment) or intentional substitution (the vial contains a different batch than the one tested). Contact the supplier and request a batch-specific COA matching the exact lot number printed on your vial. If they cannot provide one, the peptide's purity is unknown. This is common with drop-shipped peptides sourced from Chinese manufacturers and relabeled domestically—the reseller may only have one generic COA regardless of how many batches they've sold.

What If the Chromatogram Shows Multiple Peaks Close Together with No Labels?

Those unlabeled peaks represent impurities that weren't quantified in the purity calculation. For TB-500, common impurities include deletion sequences (peptides missing one or more amino acids) and diastereomers (same sequence but different stereochemistry at one residue). If the main TB-500 peak appears at 10.1 minutes but smaller peaks at 9.7 and 10.4 minutes are unlabeled, those likely represent [Des-Ala42]-TB-500 and an oxidized variant. The reported purity should account for these—if it doesn't, the percentage is inflated. A legitimate COA labels every peak above the detection threshold (typically 0.5% of total area) with either an identity or 'unknown impurity' designation. No labels means incomplete analysis.

What If the COA Lists 'HPLC Purity' But Also Shows High TFA Content?

Recalculate the effective peptide concentration manually. TFA (trifluoroacetic acid) is a counter-ion used during peptide purification and remains bound to the lyophilized powder. If the COA shows 98% peptide purity and 8% TFA content by weight, the actual peptide content is 98% ÷ 1.08 = 90.7% of the vial mass. High TFA content above 5% is common in peptides purified via preparative HPLC with TFA-based mobile phases. It doesn't indicate contamination—it's a process artifact—but it does mean the labeled peptide mass includes non-peptide weight. For dosing calculations in research protocols, use the TFA-corrected concentration. Real Peptides provides TFA quantification as standard because it directly affects reconstitution accuracy.

The Unfiltered Truth About TB-500 COA Interpretation

Here's the honest answer: most COAs in the research peptide market are issued by the supplier's own QC lab, not an independent third party—and many researchers never verify this. The difference matters enormously. An in-house COA from a peptide manufacturer has no external accountability. If their HPLC column is degraded, if their integration software is set to ignore shoulder peaks, or if they're simply reissuing the same COA for multiple batches, no regulatory body audits the practice. Independent third-party labs (ISO 17025 accredited) face external audits and lose accreditation if found manipulating data. Our team's policy at Real Peptides: every batch undergoes third-party LC-MS verification before release. It costs more. It delays shipments by 7–10 days. But it's the only way to ensure the purity claim on the COA matches the peptide in the vial. If you're procuring TB-500 for research and the supplier can't name the independent lab that generated the COA, you're trusting their word—not analytical data.

Understanding COA Limitations for Long-Term Peptide Storage

A COA represents purity at the moment of analysis—not necessarily at the moment you reconstitute the peptide six months later. TB-500 stored as lyophilized powder at −20°C maintains purity for 12–24 months, but oxidation of methionine-6 and methionine-33 occurs slowly even in the solid state if moisture is present. The COA won't reflect this. Reconstituted TB-500 in bacteriostatic water degrades faster—our team recommends single-use aliquots rather than repeated freeze-thaw cycles because each thaw introduces oxidative stress that fragments the peptide at methionine sites.

The COA also doesn't measure bioactivity. HPLC confirms TB-500 is present and pure, but it doesn't verify that the peptide retains its ability to promote actin polymerization (its primary mechanism of action). Bioactivity assays—like measuring G-actin to F-actin conversion in vitro—are separate tests not included in standard COAs. A peptide can be 99% pure by HPLC but exhibit reduced bioactivity if stored improperly or if synthesis errors occurred at critical binding residues. For cell culture or animal research requiring functional TB-500, request bioactivity data in addition to the purity COA.

Endotoxin levels are critical for in vivo research but rarely appear on standard COAs. Bacterial endotoxin contamination (measured in Endotoxin Units per milligram) can trigger immune responses in animal models independent of the peptide's intended effect. The FDA threshold for injectable biologics is <5 EU/mg. If the COA doesn't list endotoxin testing via LAL (Limulus Amebocyte Lysate) assay, assume it wasn't tested. Our experience working with research institutions shows that endotoxin contamination is the most common undetected variable causing inconsistent results across TB-500 studies—the peptide works in one lab's protocol but not another's, and the only difference is the endotoxin load in the supplier's batch.

When you're ready to source TB-500 for your research, prioritize suppliers who provide batch-specific third-party COAs with full chromatogram traces and mass spectrometry confirmation. That standard isn't universal—it's the baseline for verifiable quality. Real Peptides maintains that threshold across our full peptide collection, ensuring every vial matches the COA data before it ships. The difference between a number on a PDF and verified molecular purity is the difference between reproducible research and guesswork dressed as science.